FDA Clears Dexcom G7

Dexcom announced recently that the FDA has cleared its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with all types of diabetes ages two years and older.

Dexcom says it is working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as possible.

The Dexcom G7 now offers a more powerful and easier to use system with a small, all-in-one wearable, completely redesigned mobile app and no fingersticks or scanning required. Dexcom G7 also offers a suite of customizable alerts that can warn of high or low glucose levels and help users spend more time in range.

The system features a predictive low alert that provides a 20-minute advance warning of potentially dangerous low glucose levels so users can act quickly to avoid a hypoglycemic event. This critical feature continues to be at the forefront of the Dexcom experience, with more than 52 million Urgent Low Soon alerts acknowledged – more than 11 million of those in the middle of the night.

Users can also share information with loved ones and care teams anywhere, anytime through remote monitoring and reporting capabilities.